

Subject Index

- AAD. *See* Acidic activating domains
- ABP. *See* Androgen binding protein
- Acceptor protein, for thyroid receptor, 40
- Acidic activating domains (AAD), 30
- Acrosomal exocytosis, 460, 462, 467
- A23187 and, 466
- extracellular Ca^{2+} dependence of, 466
- inhibition of, 466
- M42 and, 466
- QNB and, 466
- tyrphostin RG50864 and, 466
- Acrosomal lamina (ALM), 242-245, 251, 255-256
- Acrosomal matrix (AMX), 241, 243-245, 255, 467-468
- Acrosomal membrane, 241, 243-245, 251, 255-256
- Acrosomal stabilizing factor, 367
- Acrosome
- enzyme targeting to, 331, 336
- EQ segment of, 241, 245-247, 249-251
- functions during fertilization, 251, 255-256
- structure-function relationships in, 240-256
- Acrosome formation, testosterone and, 272
- Acrosome-reacted sperm, and zona binding, 486
- Acrosome reaction. *See also* Spontaneous acrosome reaction; Zona-induced acrosome reaction
- A23187 and, 463, 466, 469
- and capacitation, 459-471
- characterization of, 459-560
- CTC fluorescence assay for, 460-461
- and fertilization, 459-471
- intracellular Ca^{2+} and, 461, 468-470
- M4 inhibition of, 462-463, 466, 470
- model, 467-470
- participants, 461-463
- pertussis toxin inhibition of, 463, 469
- PH-20 and, 489-490
- phorbol esters in, 463
- QNB inhibition of, 460-461, 463, 466, 469
- and sperm-zona binding, 486
- spontaneous, 460-461, 470-471, 479-480
- t complex and, 479
- tyrphostin RG50864 inhibition of, 466, 469
- ZP3 induction of, 462
- Acrosome reaction rate, and t complex sperm, 479
- Acrosome reaction stages
- fenestrate (S3), 464-467, 470
- intact (B;N+;F+), 464-469
- poised (S1;N+;F+), 464-470
- punctate (S2;N-;F-), 464-467, 470
- reacted (AR), 464-467, 470
- Acrosome reaction stage transitions
- blockage of, 460-463, 466, 469-470
- enzymes in, 469-470
- intracellular protein phosphorylation in, 468-470
- signal transduction reactions in, 467-470
- Acrosomic system, 204-205
- ACTH. *See* Adrenocorticotropin
- Actin filaments, in ectoplasmic specializations, 175, 178-186, 189-190, 192-193
- Activin, and Leydig cell steroidogenesis, 358
- Acute lymphoblastic leukemia phenotype, mutated *E2A* gene and, 300-301
- Adherens, 399. *See also* Cadherins; Cell adhesion molecules and principal cells, 404
- Adrenocorticotropin (ACTH), Leydig cell production of, 358
- Albumin, blood-to-lumen movement of, 371
- ALH. *See* Amplitude of lateral head displacement
- Amino acids, in epididymal fluids, 368
- Amplitude of lateral head displacement (ALH), of sperm motion, 417, 427-428
- AMX. *See* Acrosomal matrix
- Androgen action, in testis, 97-99
- Androgen antigrade movement
- energy dependence of, 379-380
- protein synthesis inhibition and, 380
- Androgen-binding protein (ABP)
- bidirectional secretion of, 322-325
- binding sites for, 270
- in caput epididymal lumen, 375
- endocytosis of, 271
- in proluminal androgen movement, 375-381
- Sertoli cell synthesis of, 272, 322-325, 328-329, 342, 357, 376
- and sperm fertility, 381
- steroid hormone transport by, 258
- Androgen-binding protein (ABP) levels
- cyclic changes in, 319
- reduction in, 322-325
- in reproductive tract fluids, 372-374
- Androgen-binding protein (ABP) production
- in cryptorchidism, 342-344
- spermatid influence on, 342-347

- Androgen microenvironment, of maturing spermatozoa, 371-381
- Androgen production, by Leydig cells, 392
- Androgen proluminal movement, inhibition of, 378-380
- Androgen reabsorption, receptor-mediated endocytosis, 381
- Androgen receptors (AR)
- cyclic concentration changes of, 318-319
 - first appearance of, 392
 - in Leydig cell progenitors, 157
 - as ligand-activated TF, 97
 - localization of, 98
 - in male sexual development, 56
 - molecular analysis of, 56-72
 - nuclear transport requirements of, 58-62
 - p59 association with, 33
 - in peritubular cells, 359
 - phosphorylation of, 62
 - and testicular target gene expression, 99
 - transcriptional activation domains of, 56-58
- Androgen replacement, and transcriptional gene expression, 389-391
- Androgens
- antigrade movement of, 374-381
 - cell targets of, 98
 - and epididymal sperm maturation, 371-381
 - and gonadotropin secretion, 113
 - and Leydig cell differentiation, 155-157
 - mRNA-level regulation by, 98
 - and peritubular cell differentiation, 359
 - proluminal movement of, 374-381
 - and 5 α -reduced androgens formation, 5
 - regional differences in concentration, 371-381
 - target gene regulation by, 97-99
- Androgen secretion, hemiorchiectomy and, 133-141
- Antiandrogens. *See also* Androgen receptors
- effects of, 60, 62
- Antimüllerian hormone (AMH). *See* Müllerian-inhibiting substance
- A23187, in acrosome reaction, 463, 466, 469
- ATP, and sperm motility reactivation, 439-440
- ATP level
- and flagellar beat frequency, 440
 - ROS effect on, 440, 442
- Atresia, of female germ cells, 64
- Average-path velocity (VAP), of sperm motion, 417, 427
- azh* mutation, 475
- Azoospermia
- GnRH antagonist and, 118
 - in GnRH-immunized rats, 96
 - induced, 95-96
 - testosterone and, 4
 - via sustained estradiol-testosterone release, 5
- BCF. *See* Beat cross frequency
- Beat cross frequency (BCF), of sperm motion, 417-418, 427
- Blood-epididymal barrier, 370-371, 399, 404, 406
- bouncy* mutation, 475-476
- Busulfan
- and epididymal gene expression, 392-393
 - and proenkephalin mRNA, 392
 - seminiferous tubules disruption by, 322-324
- Cadherin mRNA
- developmental changes in, 403-404
 - in epididymis, 400-407
 - longitudinal distribution of, 402-403
- Cadherins. *See also* Adherens; Cell adhesion molecules; Epithelial cadherin; Neural cadherin; Placental cadherin
- characterization of, 399-400
 - in organogenesis, 399
- Calcium ion
- and flagellar structure, 481
 - in spontaneous acrosome reaction, 471
 - in zona-induced acrosome reaction, 461, 468-470
- Calmodulin, 481
- Capacitation
- and acrosome reaction, 459-471
 - characterization of, 459-560
 - and CTC fluorescence patterns, 460-469
 - PH-20 relocalization during, 490
 - and t complex, 479
- Caput epididymis, morphological variation within, 384-385
- Carnitine, blood-to-lumen movement of, 370-371
- Carnitine concentration gradient, in epididymal fluids, 366
- Castration/androgen replacement, and transcriptional gene expression, 389-391
- CAT. *See* Chloramphenicol acetyltransferase
- Catalase, ROS destruction by, 436, 439
- Catecholamines
- regressed testes responsiveness to, 145-146
 - steroidogenic response to, 145
- Cathepsin L, 319
- Cation-dependent MPRs, 330-332, 334-336
- Cation independent MPRs, 330-331, 334-336
- Cation ionophores, in acrosome reaction, 463, 466, 469
- Cell adhesion
- in germ cell-Sertoli cell interactions, 347-349
 - in mammalian fertilization, 486
- Cell adhesion molecules (CAMs), 348. *See also* Cadherins
- identification of, 491
 - in sperm-zona binding, 487, 491

- Cell-cell interactions
 - potential regulatory agents in, 356
 - in seminiferous epithelium, 327-329, 399
 - and testis function regulation, 354-361
 - types of, 354
- Cell-cell tight junctions
 - adherence and, 399-400, 404
 - calcium dependence of, 399-400
 - and proluminal solute movement, 370-371
 - zonula occludens provision by, 370
- Ceruloplasmin, copper transport by, 355
- Cervical mucus, and sperm motility, 412-413
- Chloramphenicol acetyltransferase (CAT)
 - activity, antiandrogens and, 60, 62
- Chlortetracycline (CTC) probe
 - and capacitated sperm fluorescence patterns, 460-462, 464-469
 - in capacitation assay, 460-461, 464
- Chromatin acceptor proteins, SR binding sites
 - in, 40-42
- Chromatin acceptor sites, 40
 - nuclear matrix model of, 41
 - properties of, 41
- Clusterin (SGP-2), 79. *See also* Sulfated glycoprotein-2
 - in epididymal lumen, 367
- Computer-assisted sperm analysis (CASA)
 - sources of variation in, 427-430
 - of sperm concentration, 430
 - and sperm kinematics, 417-420, 424-426, 430-434
 - and sperm motility measurement, 419-420
 - of sperm motion characteristics, 431-433
 - technology, 426-427
- Computer-assisted sperm analysis (CASA) results
 - counting chamber depth and, 429-430
 - from semen, 430-433
 - sperm concentration effect on, 427-429
 - temperature effect on 427-428
- Conception mechanisms, West Point meeting
 - on, 19, 22
- Contraception, via sustained testosterone-estradiol release, 5
- Cryptorchidism
 - germ cell degeneration in, 341, 343
 - and Leydig cell steroidogenesis, 358
 - seminiferous tubule damage in, 358
 - Sertoli cell function in, 342
 - spermatogenesis alteration in, 445
- CTC. *See* Chlortetracycline
- Curvilinear velocity (VCL), of sperm motion, 417, 427-429, 431-432
- Cyclophilin. *See* Peptidyl-prolyl *cis-trans* isomerase
- Cystatin, 319
- Cytoplasts from elongated spermatids (CES), in spermatid-Sertoli cell binding, 347-349
- Cytotoxic agents, seminiferous tubule damage
 - by, 358
- DAG. *See* Diacylglycerol
- Desmosome-like junctions
 - in germ cell-Sertoli cell interactions, 328
 - of spermatids, 340-341
- DHT. *See* Dihydrotestosterone
- Diacylglycerol (DAG), and acrosome reaction
 - stage transitions, 468-470
- Dihydrotestosterone (DHT)
 - and E-Cad mRNA concentrations, 406
 - and increased testosterone production, 155-157
 - potency enhancement of, 157-160
 - in reproductive tract fluids, 372-374
 - and spermatogenesis maintenance, 93-94
 - testosterone conversion to, 371-372
 - and testosterone secretion, 14
- DNA-binding elements, for TFs, 37
- DNA loop domains, 164-166
 - and nuclear matrix attachments, 166
- DNA mini-loop domains, nuclear annulus
 - attachment of, 167-173
- DNA organization
 - in hamster sperm nucleus, 164-173
 - levels of, 172-173
 - in somatic cells, 164-165, 172-173
- cDNA probes, 401
- DNA-TF-SR interaction model, 39
- Doxorubicin, seminiferous tubules disruption
 - by, 322-324
- Dynein
 - in sperm flagella, 410
- E2. *See* Estradiol
- E-Cad. *See* Epithelial cadherin
- Ecdysone, 26, 42
- Ectoplasmic specializations
 - actin filaments in, 175, 178-186, 189-190, 192-193
 - domains of, 179
 - fimbrin in, 181, 184
 - nature of, 175
 - proteins associated with, 180-181, 184
 - of spermatids, 328, 340-341
- Ectoplasmic specializations function
 - adhesion hypothesis of, 190-192
 - historical perspective of, 186-190
 - intermediate filament hypothesis of, 196
 - microtubule hypothesis of, 192-196
 - in positioning spermatogenic cells, 192
- Ectoplasmic specializations structure, 175-179
 - actin zone, 180-184
 - cytoplasmic domain, 185-186
 - ectoplasmic reticulum domain, 185
 - ectoplasmic reticulum-related zone, 184

- extracellular domain, 179
integral membrane domain, 179
model of, 178-179
plasma membrane-related zone, 180
EDS. *See* Ethylene dimethanesulfonate
EGF. *See* Epidermal growth factor
Embryonic survival
frozen semen and, 455-456
heat-stressed males and, 456
intrascrotal temperature and, 453-457
 β END. *See* β -Endorphin
Endocrine infertility, gonadotropic hormones and, 107
Endocytic apparatus structure, during spermatogenesis, 263-265
Endocytic pathways, in monkey germ cells, 265-269
Endocytosis
and luminal androgen reabsorption, 381
of M6P-containing glycoproteins, 334-336
M6P receptor-mediated, 332-334
 β -Endorphin (β END)
FSH inhibition by, 358
Leydig cell production of, 358
Epidermal growth factor (EGF), 355, 357
Epididymal development, non-androgen testicular factors and, 389
Epididymal fluids
concentration gradients in, 364-368
flow rate of, 368-369
protein concentration in, 366
Epididymal gene expression
busulfan effects on, 392-393
spermatozoan regulation of, 392-393
Epididymal intraluminal fluids, 364-368
Epididymal microenvironment, 368-369
Epididymal mRNA levels, 391
Epididymal proteins
region specific, 367
species specific, 367
Epididymal sperm maturation, 371-381
Epididymis
ABP concentrations in, 372-374
androgen microenvironment of, 5
as androgen target tissue, 371-381
fluid movement through, 368-370
regulated gene expression in, 384-397
temperature-dependent functions of, 456
Epithelial cadherin (E-Cad) mRNA
developmental changes in, 403, 405-407
DHT and, 406
epididymal distribution of, 402-407
EQ. *See* Equatorial segment
Equatorial segment (EQ), 467-468
ER. *See* Estrogen receptor
Estradiol (E2)
LH secretion inhibition by, 4
spermatozoan binding sites for, 258
and sperm number, 3
Estradiol (E2) feedback, in gonadotropin production, 130
Estrogen, steroidogenesis inhibition by, 358
Estrogen receptor (ER), 28-30
chromatin acceptor proteins for, 42
hsp90 binding with, 32-33
and nuclear localization, 36
p59 protein association with, 33
Ethylene dimethanesulfonate (EDS)
and ABP levels, 323
Leydig cell elimination by, 95, 155, 322
Fecundability
abnormalities preventing, 424
predictors of, 424
Feedback inhibition, of testosterone synthesis, 5
Female germ cells
atresia of, 64
meiosis in, 64-67
and X chromosome behavior, 68
Fertility
with frozen semen, 446-447, 453-456
intrascrotal temperature and, 452-453
in PTU-treated rats, 126-127
Fertilization
acrosome reaction and, 459-471
bouncy and, 476
frozen semen and, 453
M42 inhibition of, 462
mutagenesis and, 476
sperm motility and, 410-411
Fertilization ability
gene interactions in, 477
mutations in, 476-483
Fertilization defects, insertional mutagenesis in, 476
Fetal meiotic decisions, 66-67
Fibrous sheath (FS), of mammalian spermatozoan cytoskeleton, 203
Fibrous sheath (FS) proteins, 224-225
characterization of, 227-229, 234-235
cytoskeletal characteristics of, 231-233
developmental appearance of, 229-231, 235-236
and intermediate filament proteins, 236-238
Fimbrin, in ectoplasmic specializations, 181, 184
Flagellar beat frequency, ATP and, 440
Flagellar calcium sensitivity, complex and, 481
Flagellar morphology mutations affecting, 481-482
Flagellar motion
in hyperactivation, 414
mechanism of, 409-410
photomicrographic study of, 419
in semen/cervical mucus, 412-413

- Follicle-stimulating hormone (FSH), 8
 and ABP secretion, 376
 and Leydig cell differentiation, 153-154
 photoperiod-related Sertoli cell response to, 146-147
 and primate testicular function, 107, 115-116
 and RB/CES binding, 348
 and Sertoli cell-germ cell interactions, 348, 357
 and spermatogenesis maintenance, 92-93, 96-97, 103
 spermatogenesis regulation by, 107, 129
 and spermatogenesis reinitiation, 118
 and testicular cell-cell interactions, 360
 testicular effects of, 110, 129
- Follicle-stimulating hormone receptor (FSHR)
 levels, cyclic changes in, 317-319
- Fractal dimension, and sperm head trajectory shape, 418
- FS. *See* Fibrous sheath
- FSH. *See* Follicle-stimulating hormone
- FSHR. *See* Follicle-stimulating hormone receptor
- Fura-2, and sperm fluorescence patterns, 466
- Galactosyltransferase (GT)
 as CAM, 487
 in sperm-zona binding, 489-490
 in *t*+ sperm populations, 479
- Gametogenesis
 FSH in, 116
 sexual dimorphism in, 64-66
- Gap-junctions, in spermatid-Sertoli cell interactions, 328, 341
- Gene expression
 developmental aspects of, 392
 epididymal sites of, 385-388
 regional epididymal specificity of, 385-388
 steroid action on, 47
 transcriptional regulation of, 389-393
- Gene regulation
 cell-type specific, 38
 TF-SR interaction in, 39-40
- Genetic defects, germ cell depletion in, 322-324
- Gene transcriptional activity, SR and, 29
- Germ cell. *See also* Sperm; Spermatid; Spermatozoa
- Germ-cell differentiation
 Sertoli cells and, 66
 XX chromosome constitution and, 66-67
 Y chromosome presence and, 66-67
- Germ cell number, agents causing reduction in, 322-325
- Germ cells
 in adrenal cortex, 66
 cell-cell interaction effects on, 328
 M6P receptor-mediated endocytosis in, 332-334
- Germ cell-Sertoli cell interactions
 and ABP bidirectional secretion, 322-325
 adhesion factors in, 347-349
 desmosome-like junctions in, 328
 effects of, 327-329
 mechanisms of, 347-349
 mediators of, 328, 341, 347-349
 MPR mediation of, 327-336
- Germ-cell sex, first appearance of, 66
- Germinal cells, Sertoli cell effects on, 355
- GH. *See* Growth hormone
- Glucocorticoid receptor (GR), 28-31
 hsp90 stabilization of, 32
 p59 protein association with, 33
- Glucose-6-phosphate dehydrogenase (G6PD), X chromosome inactivation and, 68-69
- Glutathione peroxidase/reductase system, ROS destruction by, 436
- Glycerolphosphorylcholine (GPC), progressive epididymal concentrations of, 364, 366
- Glycoprotein ZP3
 in acrosome reaction stage transitions, 469-470
 in induced acrosome reaction, 462
 and signal transduction chain, 464-466
 sperm membrane receptors for, 462-463, 469
- Glycoprotein ZP3 modifications, TPA treatment and, 465-466
- Gonadotropin-releasing hormone (GnRH), and spermatogenesis, 92, 110
- Gonadotropin-releasing hormone (GnRH) antagonist
 and azoospermia, 113
 and DHT/testicular testosterone concentrations, 114-115
 gametogenesis inhibition by, 112
- GPC. *See* Glycerolphosphorylcholine
- Gpd gene, X chromosome inactivation and, 69
- G proteins
 pertussis toxin inactivation of, 463
 in zona-induced acrosome reaction, 463, 469-470
- GR. *See* Glucocorticoid receptor
- Growth hormone (GH), 8
 and mouse germ cell development, 107
- G6PD. *See* Glucose-6-phosphate dehydrogenase
- GTP-binding regulatory proteins. *See* G proteins
- hCG. *See* Human chorionic gonadotropin
- Heat shock protein (hsp90)
 functions of, 33
 GR stabilization by, 32
 and nuclear localization, 36
 SR interaction with, 28, 32-34
- Hemiorchidectomy
 and androgen/LH secretion, 133-141
 Sertoli cell number reduction by, 324

- hMG. *See* Human menopausal gonadotropin
- Homeobox genes (Hox)
characterization of, 300-304, 309
and differentiation regulation, 300-301
as TFs, 300
- Hormone response element (HRE), 35
- hotfoot mutation, 475-476
- HOX genes. *See also* Homeobox genes
retinoic acid and, 304
- Hox genes expression
and embryogenic structural organization,
304-305
pattern of, 304
tissue specificity of, 305-308
- HPRT. *See* Hypoxanthine phosphoribosyl
transferase
- Hprt gene, X chromosome inactivation and,
68-69
- Human chorionic gonadotropin (hCG)
effects of, 108
and spermatogenesis, 116
and testosterone spermatogenesis role, 113
- Human menopausal gonadotropin (hMG), and
gametogenesis, 110, 116
- Human sex steroid-binding protein (hSBP).
See also Sex steroid-binding protein
endocytosis of, 265-273
purification of, 260
- Hyperactivation, 480-481
CASA analysis of, 420
as fertilizing capacity biomarker, 415
flagellar beats in, 414
sperm exhibition of, 413-415
- Hypogonadotropism, hCG therapy in, 116
- Hypothyroidism. *See also* Transient hypo-
thyroidism
PTU induction of, 124-128
and testicular development, 123-130
- Hypoxanthine phosphoribosyl transferase
(HPRT), X chromosome inactivation and,
68-69
- IAM. *See* Inner acrosomal membrane
- IB15 gene, 389
and PPI, 385
- IB15 mRNA
distribution of, 385-386
levels distribution, 392
- Idiopathic infertility, ROS formation and, 436
- IGF. *See* Insulin-like growth factors
- IgG. *See* Immunoglobulin G
- Immobilin, in epididymal lumen, 367
- Immunoglobulin G (IgG), blood-to-lumen
movement of, 371
- Implantation fossa, 165-166, 173
- Infection, and sperm function damage,
438-439
- Inhibin, 319, 329
and Leydig cell steroidogenesis, 154, 358
PModS-stimulated production of, 100
- Inhibin production
by Sertoli cells, 358
spermatid influence on, 342-343
- Inner acrosomal membrane (IAM), 467-468
PH-20 and, 490
- Inositol
blood-to-lumen movement of, 371
in epididymal fluids, 366
- Insulin-like growth factor-I (IGF-I)
and androgen production, 160-161
and Leydig cell steroidogenesis, 154
peritubular cell production of, 357
Sertoli cell production of, 355
stimulatory effects of, 357
T3-stimulated production of, 123
- Insulin-like growth factor-II (IGF-II)
CI-MPR binding to, 330
in testes, 335
- Interleukin-1 (IL-1), Sertoli cell production of,
355, 358-359
- Intrascrotal temperature
and embryonic survival, 453-457
and fertility, 452-453, 455-457
and male infertility, 445-446
scrotal insulation and, 447-448
and spermatogenesis, 445-446, 455
and sperm motility, 449-451, 455-457
and TSC, 449-451, 455-457
- Ion concentration gradient, in epididymal
fluids, 364-365
- Ion reabsorption, in epididymal fluids, 365-366
- Ischemia, and ABP levels, 322-323
- α -Lactalbumin-like protein, in epididymal
lumen, 367
- Lactate production, puberty delay and, 146-147
- Lag phase, following SR-binding, 27
- Leu-enkephalin. *See* Proenkephalin pentapeptides
- Leydig cell differentiation
androgen involvement in, 155-157
FSH/LH promotion of, 153-154
hCG facilitation of, 154
hormonal control of, 152-161
- Leydig cell function, 144-146
regulation of, 1, 4
- Leydig cell morphology
agents altering, 358
LH and, 9
testosterone secretion inhibition and, 7-8
- Leydig cell-peritubular cell interactions, 359
- Leydig cell peroxisomes, and testosterone
production, 9-10
- Leydig cell population, mesenchymal cells
and, 11-12, 14

- Leydig cell progenitors
ARs in, 157, 161
enhanced DHT action on, 157-160
IGF-I stimulatory effect on, 160-161
- Leydig cells
activin/inhibin production by, 358
androgen production by, 153, 392
ARs in, 98
early study of, 17
EDS elimination of, 95, 155, 322
estrogen production by, 358
photoperiod-related changes in, 144-146
POMC derivatives produced by, 358
progenitors of, 152-153
5 α -reduced androgen production by, 153
regulation of, 5-7
Sertoli cell influence on, 358-359
smooth endoplasmic reticulum of, 7-8
and spermatogenesis, 94-95, 99, 103, 107
in testicular function, 354
testosterone production by, 5, 9-10, 81, 90, 399
- Leydig cell-Sertoli cell interactions, 358-359
- Leydig cell steroidogenesis
Sertoli cell secretions and, 358
TGF- β inhibition of, 328
- LH. *See* Luteinizing hormone
- LHRH. *See* Luteinizing hormone releasing hormone
- LIN. *See* Linearity
- Linearity (LIN, L), of sperm motion, 417, 427-429, 431-432
- Lonidamine, seminiferous tubules disruption by, 322-323
- Luteinizing hormone (LH)
and Leydig cell differentiation, 153-154
and Leydig cell smooth endoplasmic reticulum, 8
and progesterone-testosterone conversion, 8-9
spermatogenesis regulation by, 107, 129
steroidogenesis inhibition by, 7-8
and testicular cell-cell interactions, 359-360
and testosterone production, 90
- Luteinizing hormone (LH) suppression, and azoospermia, 95-96
- Luteinizing hormone releasing hormone (LHRH) and germ cell reduction, 322-323
and Sertoli cell number reduction, 322-324
- Luteinizing hormone secretion
following hemiorchidectomy, 133-141
testosterone inhibition of, 4
- Lysozyme gene, and SREs, 37
- MAD. *See* Mean angle of deviation
- Major excreted protein (MEP)
factors stimulating synthesis of, 328-329
procathepsin L as, 328-329
- Male fertility
assessment problems, 425
sperm motility and, 409
testosterone-estradiol temporal effects on, 4
- Male germ cells
meiosis of, 64-70
X chromosome inactivation in, 67-70
- Male infertility
FSH/hCG/hMG treatment for, 116
intrascrotal temperature and, 445-446
ROS formation and, 436-437
sperm motility disorders in, 424-426
- Mammalian testis, perfusion of, 1-2
- Mannose 6-phosphate (M6P) glycoproteins
Sertoli cell secretion of, 334-335
- Mannose 6-phosphate receptor (CI-MPR)
endocytosis mediation by, 330
growth factors binding to, 330
and IGF-II receptor, 330, 335
Sertoli cell synthesis of, 331
- Mannose 6-phosphate receptor glycoproteins, and endocytosis, 334-336
- Mannose 6-phosphate receptor-mediated endocytosis, 332-334
- Mannose 6-phosphate receptors (MPRs)
cation-dependent (CD) form, 329-332, 334-36
cation-independent (CI) form, 329-331, 334-336
characteristics of, 329-330
as germ cell-Sertoli cell interaction mediators, 327-336
in germ cells/Sertoli cells, 330-332
and lysosomes, 329
- Mean angle of deviation (MAD), CASA analysis of, 432
- Meiosis
dimorphism of, 67-68
of female germ cells, 64-67
of male germ cells, 64-70
- α -Melanocyte stimulating hormone (α -MSH), Leydig cell production of, 358
- MEP. *See* Major excreted protein
- Metabolic inhibitors, and androgen proluminal movement, 378-380
- Met-enkephalin. *See* Proenkephalin pentapeptides
- 3-O-Methyl-D-glucose (30 MG), blood-to-lumen movement of, 371
- M42 monoclonal antibody
and acrosomal exocytosis, 466
acrosome reaction inhibition by, 462-463, 466, 470
- MIS. *See* Müllerian-inhibiting substance
- MMTV. *See* Mouse mammary tumor virus
- Mouse mammary tumor virus (MMTV), SREs in, 31, 37-38
- MPR. *See* Mannose 6-phosphate receptor

- α -MSH. *See* α -Melanocyte stimulating hormone
- M6P. *See* Mannose-6-phosphate
- Müllerian-inhibiting substance (MIS)
characterization of, 77, 329
and gonadal masculinization, 74-75
production of, 77-79
and testicular differentiation, 74-82, 85-86
- Mutations
and fertilization defects, 476
in fertilization studies, 474-475
and male fertility, 474
and sperm-egg interactions, 476, 478
and sperm fertilizing ability, 476-483
and sperm function, 474-483
and sperm head morphology, 475
and sperm motility, 475, 479-481
- NAP. *See* Nucleoacidic protein
- National Institute of Child Health and Human Development (NICHD) Workshop on the Testis, 322
- NDAA. *See* *N*-(*n*-dodecyl)-9-aminoacridine
- Nerve growth factor (NGF), 356-357
- Neural cadherin (N-cad), in testis/seminiferous tubules, 348
- Neutrophil concentration, and sperm function damage, 438-439
- New York Academy of Sciences Meeting (1952), 19
- Nexin, in sperm flagella, 410
- NGF. *See* Nerve growth factor
- Nigericin, in acrosome stage transitions, 466
- N*-(*n*-dodecyl)-9-aminoacridine (NDAA), and sperm fluorescence patterns, 464
- Non-hsp proteins, and unactivated PR complex, 33
- Nuclear annulus
DNA loop association with, 165-173
DNA mini-loops attachment to, 167-173
structure/position of, 166-167
- Nuclear localization, ER-hsp90 interaction and, 36
- Nuclear localization signal
for SRs, 36
and zinc finger region, 35-36
- Nuclear matrix, DNA loop domains specific sites in, 166
- Nucleoacidic protein (NAP), 40-42
- OAM. *See* Outer acrosomal membrane
- ODC. *See* Ornithine decarboxylase
- ODF. *See* Outer dense fibers
- 3OMG. *See* 3-*O*-Methyl-D-glucose
- Ornithine decarboxylase (ODC) production, testosterone effect on, 99-100
- Outer acrosomal membrane (OAM), 467-498
- Outer dense fiber proteins
developmental expression of, 209-210
intracellular localization of, 211-214
- Outer dense fibers (ODF)
antibodies to, 207-208
formation of, 219-222
isolation of, 204-205
of mammalian spermatozoon cytoskeleton, 203-214
polypeptide composition of, 205-206
structure of, 204
- Paracrine factors
peritubular myoid cell production of, 357-358
in Sertoli cell function, 340
Sertoli cell production of, 355-357
- Paracrine factors mediation, of testicular cell-cell interactions, 359-361
- pep. *See* Peptidyl-prolyl *cis-trans* isomerase
- Peptidyl-prolyl *cis-trans* isomerase (PPI), 385-386
constitutive expression of, 390-391, 397
function of, 394
principal cell secretion of, 385
- Peptidyl-prolyl *cis-trans* isomerase (PPI)
mRNA, 385-386
distribution of, 385-386
- Peptidyl-prolyl *cis-trans* isomerase (PPI)
mRNA levels
androgen replacement and, 389-391
in epididymis, 386
- Perforatorial proteins
developmental expression of, 209-210
distributional pattern of, 214-219
- Perforatorium
antibodies to, 208
formation of, 219-222
isolation of, 204-205
polypeptide composition of, 205-206
structure of, 204
- Perinuclear theca (PT), of mammalian spermatozoon
cytoskeleton, 203
- Peritubular cell-Sertoli cell interactions, 357-358
- Peritubular myoid cells
EGF receptors on, 357
growth factors produced by, 359
Leydig cell interactions with, 359
paracrine factors produced by, 357-358
PModS secretion by, 100, 359
in testis cytoarchitecture, 354
testosterone action mediation by, 98, 100
- Pertussis toxin, in acrosome reaction blockage, 463, 469
- p56, ZP3-binding activity of, 462

- PGK. *See* Phosphoglycerate kinase
Pgk genes, in spermatogenic cells, 69
PH-20
 in acrosome-reacted sperm-zona binding, 488
 in epididymal maturation, 489-490
 modification of, 489-490
 post-testicular changes in, 489
 relocalization during capacitation, 490
pH
 and acrosome reaction, 468
 of intraluminal fluids, 366
 of spermatozoa, 368
 and sperm fluorescence pattern changes, 464
pH probes, in sperm capacitation, 464
Phorbol esters, and acrosome reaction, 463
Phosphoglycerate kinase (PGK), X chromosome inactivation and, 68-69
Phospholipase C (PL-C), in zona-induced acrosome reaction, 463, 469-470
Photoperiod-related changes
 in FSH release, 146-147
 in Leydig cells, 144-146
 in testicular function, 143-144
Placental cadherin (P-Cad) mRNA
 concentration changes, 406
 developmental changes in, 403-407
 epididymal distribution of, 402-407
Plakoglobin, in ectoplasmic specializations, 180
Plasma membrane (PM), 467-468
Plasminogen activator production, testosterone effect on, 99
PL-C. *See* Phospholipase C
PM. *See* Plasma membrane
PModS
 androgen control of, 357
 forms of, 357
 Sertoli cell regulation by, 100, 357-359
PMSG. *See* Pregnant mare serum gonadotropin
p95(TK)
 in acrosome reaction, 462, 469-470
 in spontaneous acrosome reaction, 471
 as ZP3 receptor, 462, 469-470
Population kinetics, in fluorescence pattern loss, 464-465
PR. *See* Progesterone receptor
Pregnant mare serum gonadotropin (PMSG), and gametogenesis, 110
Pregnenolone, testosterone biosynthesis from, 6
Principal cell
 protein transcripts, 386-388
Principal cells
 characterization of, 384-385
 epididymis-specific proteins secreted by, 385
 tight junctions between, 404
Procathepsin L (cyclic protein 2), Sertoli cell secretion of, 328-329
Proenkephalin
 functional role of, 393-397
 principal cell secretion of, 385
Proenkephalin mRNA levels
 busulfan effect on, 392
 castration/androgen replacement and, 390
 regional differences in, 386
 time course of, 391
Proenkephalin pentapeptides, 385
 epididymal localization of, 395-397
Progesterone, spermatozoan binding sites for, 258
Progesterone receptor (PR), 28-29
 chromatin acceptor sites for, 40-42
 higher order structure of, 34
 hsp90 binding with, 32-33
 p59 protein association with, 33
Proliferin, CI-MPR binding to, 330
6-Propyl-2-thiouracil (PTU)
 and body growth, 124
 and hypothyroidism, 124
 and testis size/sperm production, 127-128
Prostatic hyperplasia, androgen dependence of, 5
Protamine mRNA expression
 in spermatids, 278, 285-287, 297-298
 timing of, 277-278, 280-285, 289, 292, 294
Protein B/C
 androgen-dependent gene transcription, 389
 function of, 394
 principal cell secretion of, 385
Protein B/C mRNA levels
 castration/androgen replacement and, 389-390
 time course of, 392
Protein D/E
 androgen-dependent gene transcription, 389
 carboxypeptidase Y homology with, 394
 principal cell secretion of, 385
Protein D/E mRNA levels
 castration/androgen replacement and, 389-390
 time course of, 392
Protein kinase C (PK-C), in zona-induced acrosome reaction, 463, 468-470
Protein microenvironment, and spermatozoan development, 366
Proto-oncogenes, as regulatory genes, 42-43
PT. *See* Perinuclear theca
PTU. *See* Propyl-2-thiouracil
QNB. *See* 3-Quinuclidinyl benzilate
3-Quinuclidinyl benzilate (QNB)
 and acrosome reaction, 460-463, 466
 B-to-S1 transition blockage by, 469
R. *See* Receptor proteins
Radiation
 and ABP levels, 322-323, 344-347
 seminiferous tubule damage by, 358
 and Sertoli cells, 344-347

- Radixin, in ectoplasmic specializations, 180
- RAR. *See* Retinoic acid receptor
- RB. *See* Residual bodies
- RBF. *See* Receptor binding factors
- Reactive oxygen species (ROS)
- enzymes destroying, 436
 - and human spermatozoa, 436-442
 - toxicity to spermatozoa of, 436
- Reactive oxygen species (ROS) effect
- on spermatozoan ATP level, 439-440, 442
 - on sperm motility/viability, 439-441
- Reactive oxygen species (ROS) formation
- and idiopathic infertility, 436
 - in infertile males, 437
 - by neutrophils, 438-439
 - sperm washing procedures effect on, 438
- Reactive oxygen species (ROS) scavengers, 441
- and X + XO treated spermatozoa, 442
- Receptor binding factors (RBF), 41-42
- Receptor domains, 28
- Receptor phosphorylation, 34-35
- and cytosolic PR, 33
- 5 α -Reductase, in testosterone-to-DHT conversion, 371-372
- Regulatory genes
- classes of, 44
 - early genes as, 42-43, 47
- Regulatory gene transcription, SR action on, 45-47
- Reproduction and Human Welfare, Ford Foundation Report on, 22, 24
- Residual bodies (RB), in spermatid-Sertoli cell binding, 341, 347-349
- Retinoic acid receptor (RAR) levels, in spermatogenesis, 316-317
- RU486, AR agonist action of, 62
- SCP-2. *See* Sterol carrier protein-2
- Scrotal insulation. *See also* Intrascrotal temperature
- and rectal temperatures, 448, 455-456
 - and respiratory rates, 448, 455-456
 - and spermatozoan metabolism, 456
- SDS. *See* Sodium dodecyl sulfate
- Semen analysis
- CASA technology and, 424-426
 - frozen semen and, 447, 452-453
 - motion characteristics, 431-433
 - problem areas in, 425-426
 - semen collection for, 426
 - sperm concentration estimates, 430
- Seminiferous epithelium cycle, receptor expression during, 313-320
- Seminiferous growth factor (SGF), 360
- Seminiferous tubule disruption
- agents causing, 322-324
 - and Leydig cell morphology, 358
- Seminiferous tubule fluid (STF), testosterone concentration in, 91, 94, 96, 98-99, 101, 115
- Seminiferous tubules, hCG effect on, 108
- Sertoli cell function
- paracrine factors in, 340
 - PModS effects on, 359
 - spermatid regulation of, 340-349
- Sertoli cell-germ cell interactions, 355-357.
- See also* Germ cell-Sertoli cell interactions
 - desmosome-like junctions in, 328
 - NGF in, 356-357
- Sertoli cell products, functional mode distribution of, 320
- Sertoli cell response, to testosterone, 100, 103
- Sertoli cells, 18, 22, 71
- and ABP synthesis, 272, 322-325, 328-329, 342, 355, 376
 - ARs in, 98
 - Cell-cell interaction effects on, 328
 - in copper transport, 355
 - cyclic changes in, 313-314
 - cyclic RAR levels in, 316
 - ectoplasmic specializations in, 175-197, 348
 - functional modes of, 315-320
 - and germ-cell differentiation, 66, 328
 - germinal cell interaction with, 355-357
 - growth factors produced by, 355-357
 - IGF-I production by, 123
 - IL-1 production by, 355, 358-359
 - in iron transport, 315, 355
 - lactate production by, 146-147, 355
 - Leydig cell interaction with, 358-359
 - M6P receptor-mediated endocytosis in, 332-334
 - neonatal LHRH antiserum reduction of, 322-324
 - peritubular cell interaction with, 357-358
 - photoperiod-related changes in, 146-147
 - PModS stimulation of, 100
 - pyruvate production by, 355
 - radiation effects on, 344-347
 - RB/CES binding to, 347-349
 - roles of, 327-328
 - SGP-2 production by, 79-81, 100-101
 - spermatid action on, 347-349
 - structural relationships with spermatids, 340-341
 - sulfated glycoprotein secretion by, 331, 335
 - testicular cadherin in, 348
 - in testis cytoarchitecture, 354
 - transferrin synthesis by, 315, 328, 355
 - T3 receptors in, 123
- Sertoli cell-secreted proteins, 100, 327-329
- M6P-containing glycoproteins, 334-336
 - testosterone action on, 99
- Sertoli cell-spermatid binding, CES and, 347-349

- Sex steroid-binding protein (SBP). *See also*
Human sex steroid-binding protein
endocytosis of, 258-273
steroid hormone transport by, 258
SGF. *See* Seminiferous growth factor
SGP-2. *See* Sulfated glycoprotein-2
Signal transduction chain
in acrosome reaction stage transitions,
467-470
ZP3-initiated, 464-466
Single cell kinetics, in fluorescence pattern
loss, 464-465
Sodium dodecyl sulfate (SDS), in cytoskeletal
isolation, 204
Somatomedin-C. *See* Insulin-like growth factor-I
Sperm. *See also* Germ cell; Spermatid;
Spermatozoa
Spermatid numbers, and Sertoli cell function
parameters, 344-347
Spermatids
desmosome-like junctions in, 340-341
structural relationships with Sertoli cells,
340-341
Spermatogenesis
androgen regulation of, 90-103
cyclic FSHRmRNA levels in, 317-319
early studies of, 18-19
in GnRH-immunized rats, 94-96
heat alteration of, 445-446
homeobox genes expression in, 300-309
initiation of, 107-110
intrascrotal temperature and, 445-446
Leydig cell tumor and, 110
maintenance of, 107-108, 110-116
morphological events in, 340-341
nonandrogenic Leydig cell products and, 94-95
peritubular cell-Sertoli cell interaction and, 359
pituitary hormones dependence of, 107
in primates, 107-119
protamine mRNA transcription in, 277-278
qualitatively/quantitatively normal, 108
RAR in, 316-317
reinitiation of, 108, 116-118
SBPs role in, 272
in seasonal breeders, 143-146
seminiferous epithelium cycle in, 313-320
Sertoli cell changes in, 313
sex chromosomes role in, 64-72
and testicular testosterone, 114-115
testosterone-dependence of, 90
testosterone maintenance of, 91-95
testosterone restoration of, 95-97
transferrin receptor mRNA levels in, 315-319
vitamin A deficiency and, 316-317
X chromosome inactivation in, 67-70
in XO,Sxr males, 70-71
Y chromosome role in, 66, 70-71
Spermatogenesis initiation
FSH role in, 110
LH in, 108
testosterone role in, 108-110
Spermatogenesis maintenance
FSH and, 92-93
testosterone concentration and, 91-95
Spermatogenesis modifications, scrotal
temperature and, 446-457
Spermatogenesis suppression
by GnRH antagonist, 112
and testicular somatic cell control/function,
143-149
testosterone-estradiol synergism and, 4
Spermatogenic cell endocytosis, of
M6P-glycoproteins, 334-336
Spermatozoa. *See also* Germ cell; Sperm;
Spermatid
in epididymal microenvironments, 364-381
lipid peroxidation sensitivity of, 436
in proenkephalin gene expression regulation,
392-393
steroid-binding sites on, 258
structural domains in, 240
Spermatozoan cytoskeletal elements
biogenesis of, 203-222
components of, 203-204
SDS-insoluble proteins of, 203
Sperm concentration gradient, in epididymal
fluids, 365-366
Sperm dysfunction models
azh, 475
bouncy, 475-476
hotfoot, 475-476
t complex, 475-482
Sperm-egg interactions
defects in, 476, 478-479
t complex and, 478-479, 481
Sperm exocytosis, initiation of, 486
Sperm fertility, ABP and, 381
Sperm flagella, structure of, 409-411
Sperm fluorescence patterns
with CTC, 460-462, 464-469
with fura-2, 466-467
with NDAA, 464, 467
Sperm function
genetics of, 4744-483
neutrophil/infection damage to, 438-439
Sperm kinematics, 416-418. *See also* Sperm
motility
CASA and, 417-420, 424-426, 430-434
Sperm morphology
mutations in, 475
Sperm motility
ATP reactivation of, 439-440
biological importance of, 410-412
characteristics of, 409-420

- characterization of, 416-418
components of, 416
in epididymis, 367-368
female tract properties and, 411
generation of, 409-410
hyperactivated, 413-415
intrascrotal temperature and, 449-451
and male fertility, 409
measurement of, 419-420
mutations in, 479-482
in semen, 412-413
and t complex genes, 475, 478-482
in uterus/oviduct, 413-415
velocities of, 417-418
X + XO effect on, 439, 442
- Sperm motility measurement
by CASA, 419-420
indirect methods for, 419
- Sperm motility parameters, definition of, 417-418
- Sperm number
combined testosterone-estradiol effect on, 3
estradiol effect on, 3
testosterone effect on, 3
- Sperm production
pituitary hormone replacement and, 424
in PTU-treated rats, 126
- Sperm proteins
PH-20, 488-490
post-testicular modification of, 486-491
- Sperm QNB binding protein (SQBP)
as Ca^{2+} channel, 463
and intracellular Ca^{2+} , 469
- Sperm-zona binding
acrosome reaction and, 486
CAMs in, 487
PH-20 in, 488
- Spontaneous acrosome reaction, 479-480.
See also Acrosome reaction; Zona-induced acrosome reaction
- Sputnik, impact of, 19
- Spy gene, 71
- SQBP. *See* Sperm QNB binding protein
- SR. *See* Steroid receptor
- SRU. *See* Steroid response unit
- SRY DNA sequence, as *TDF* gene candidate, 74
- Steel (*Sl*) mutation, and sterility, 474
- Sterility, mutations causing, 474
- Steroid action
basic mechanism of, 26-29
cascade model of, 43-45
on chromatin structure, 45
on gene expression, 47
- Steroid-binding domain IV
and hsp90 binding, 33
and protein activity inhibition, 30
- Steroid hormone action, 35
model of, 97
- Steroidogenesis inhibition, by LH, 7-8
- Steroid receptors (SR), 26-27, 29
complex formation, 27
DNA-binding domain (II and III), 28-30
nuclear localization sequences of, 35-36
primary structure of, 29-31
protein interaction with, 32-34
quaternary structure of, 31-34
and regulatory gene transcription, 45-47
steroid-binding domain (IV), 30-31
TF interaction with, 37-38
- Steroid-response elements (SRE), 27-28, 31, 35, 46-47
distribution of, 37
palindromic structure of, 36
SR binding to, 36-47
- Steroid response unit (SRU), 37
- Sterol carrier protein-2 (SCP-2), 10-11
- STR. *See* Straightness
- Straightline velocity (VSL), of sperm motion, 417, 427, 432
- Straightness (STR), of sperm motion, 417
- Sulfated glycoprotein-2 (SGP-2)
characterization of, 79
levels per testis of, 102-103
production of, 79-81
and testicular differentiation, 75-82, 85-86
- Superoxide dismutase, ROS destruction by, 436, 439
- Sustained release, of testosterone-estradiol, 4-5
- Ta3. *See* Triiodothyronine
- Ta4. *See* Thyroxine
- TAF. *See* Transcriptional activating function (TAF)
- t complex
and acrosome reaction, 479
chromosome locus of, 476
and flagellar Ca^{2+} sensitivity, 481
lethal factors in, 476
and regulatory proteins, 479
and sperm fertilizing ability, 476-479
sperm genotypes in, 476-481
and sperm motility, 475, 478-482
and sperm transport, 478-479
testis-expressed genes in, 477-478
- Tdy* gene, and testicular differentiation, 74
- Testicular cell differentiation
biochemical evidence for, 75-82
SGP-2 and, 75-82, 85-86
ultrastructural evidence for, 75
- Testicular changes, in PTU-treated rats, 125-126
- Testicular development
thyroid hormones and, 122-124
transient hypothyroidism and, 123-130
- Testicular differentiation, in XX mouse
gonadal graft, 74-87

- Testicular function in primates
 FSH effects on, 107, 115-116
 testosterone effects on, 107-119
- Testicular macrophages
 FSH-stimulated lactate production by, 148
 seasonally-related decreases in, 147-148
- Testicular organomegaly, induction of, 124
- Testicular perfusion, 1-2
 testosterone synthesis in, 3
- Testicular somatic cell function, spermatogenesis suppression and, 143-149
- Testicular temperature, and spermatogenesis, 445-446
- Testicular testosterone, in GnRH antagonist-treated monkeys, 114
- Testicular testosterone secretion, hCG and, 144-145
- Testis
 androgen action in, 97-99
 cadherin in, 348
 cytoarchitectural cells of, 354
- Testis-expressed genes, in t complex, 477-478
- Testis growth, in PTU-treated rats, 125
- Testis research
 landmarks in, 19-24
 1949-1950, 17-19
 1950-1975, 24
- Testosterone
 and ABP secretion, 376
 and acrosome formation, 272
 and azoospermia, 4
 biosynthetic pathways, 6
 as effective testis androgen, 94
 epididymal concentration gradient of, 371-373
 and primate testicular function, 107, 129
 in Sertoli cell function, 340
 and spermatogenesis initiation, 108-110
 and spermatogenesis maintenance, 110-116, 129
 and spermatogenesis reinitiation, 116-118
 spermatozoan binding sites for, 258
 and sperm number, 3
 and testicular cell differentiation, 81, 129
 in vitro production of, 12-14
- Testosterone action
 peritubular myoid cell mediation of, 98
 Sertoli cell mediation of, 98
 on Sertoli cell proteins, 99-103
- Testosterone concentration
 and spermatogenesis maintenance, 91-95, 98
 in STF, 91, 94, 96, 98-99, 101
- Testosterone levels, in PTU-treated rats, 127
- Testosterone metabolites, formation of, 5
- Testosterone production
 by Leydig cell progenitors, 155-157
 Leydig cells and, 5, 81, 90
 LH stimulation of, 12-14
- Testosterone secretion
 smooth endoplasmic reticulum amount and, 7
 species differences in, 7
- Testosterone synthesis
 autoregulation of, 5
 by perfused testis, 3
- TF. *See* Transcription factors
- Thyroid hormones
 and spermatogenesis, 123
 and testis development, 122-130
- Thyroid-stimulating hormone (TSH), 8
 in PTU-treated rats, 124
- Thyroxine (T4), in PTU-treated rats, 124
- Tight junctions, 370-371, 399-400, 404
- TK. *See* Tyrosine kinase
- Total sperm count (TSC), intrascrotal temperature and, 449-451
- Transcriptional activating function (TAF), 30-31
- Transcriptional activation domains, of AR, 56-58
- Transcriptional expression patterns, 390-391
- Transcription factors (TF), 47
 receptor-protein interaction with, 38
 SR interaction with, 37-38
 in steroid action, 37-40
 steroid regulation of, 42-43
- Transducin. *See* G proteins
- Transferrin
 iron delivery via, 328, 355
 in spermatogenesis, 315
- Transferrin receptor mRNA levels, in spermatogenesis, 315, 319
- Transferrin synthesis
 by Sertoli cells, 100, 331, 355
 testosterone and, 100-103
- Transforming growth factor- α (TGF- α)
 and Leydig cell steroidogenesis, 154
 peritubular cell production of, 357
 Sertoli cell production of, 355, 357
- Transforming growth factor- β (TGF- β)
 actions of, 328-329, 357
 CI-MPR binding to, 330
 peritubular cell production of, 357
 Sertoli cell production of, 355, 357
- Transgenic mice
 fertilization defects in, 476
 insertional mutagenesis in, 476
- Transient hypothyroidism. *See also* Hypothyroidism and testicular development, 123-130
- Triiodothyronine (T3)
 and IGF-I production, 123
 in PTU-treated rats, 124
- Tryptophan oxygenase (TO) gene, SREs in, 37
- TSC. *See* Total sperm count
- TSH. *See* Thyroid-stimulating hormone

- Tubulobulbar complexes, in spermatid-Sertoli cell interactions, 340-341
- Tyrosine aminotransferase (TAT) gene, SREs in, 37
- Tyrosine kinase (TK), in acrosome reaction, 462, 469-470
- Tyrphostin RG50864, in stage transition inhibition, 466, 469
- Urea, blood-to-lumen movement of, 370
- Uteroglobin gene, SREs in, 37
- VAP. *See* Average-path velocity
- Vasectomy, and luminal fluid flow rate, 369
- Vasovasostomy, and luminal fluid flow rate, 369
- VCL. *See* Curvilinear velocity
- Vinculin, in ectoplasmic specializations, 180
- Vitamin A deficiency, seminiferous tubule damage by, 358
- Vitamin D₃, photoperiod-related Sertoli cell response to, 147
- Vitellogenin gene, SREs in, 37-38
- VSL. *See* Straightline velocity
- White-spotting (W)* mutation, and sterility, 474
- Wild type (+)/t complex recombination, 476
- WOB. *See* Wobble
- Wobble (WOB), of sperm motion, 417
- X. *See* Xanthine
- Xanthine (X) + xanthine oxidase (XO)
ROS production by, 439
scavenger protection against, 442
- X-chromosome, and male/female meiosis, 65-66
- X chromosome behavior
in female gametocytes, 68
in spermatogenesis, 67-70
- XO. *See* Xanthine oxidase
- XX germ cells, in testis, 66-67
- XX gonad
MIS masculinization of, 74-75
sex reversal of, 74-75
testicular cell differentiation in, 75-82
- XX gonadal graft, testicular differentiation mechanism in, 83-87
- XX testicular differentiation induction
conditions required for, 83-87
gonadal graft age and, 85
grafting sites and, 83
host kidney tissue interaction, 86
host sex/adjacent mesonephros and, 84-85
oocyte loss and, 86-87
testosterone and, 85
time course of, 85-86
- XXY gonocytes
differentiation path of, 66
morphology of, 66
- XXY "Klinefelter" mice, 66-67
- Y chromosome
and germ-cell differentiation, 66-67
during male meiosis, 69-70
spermatogenesis role of, 70-71
- Zinc fingers
nuclear localization signals and, 35-36
of SR DN-binding domains, 30, 33, 36-37
- Zona-induced acrosome reaction, 461-470.
See also Acrosome reaction; Spontaneous acrosome reaction
- Zona pellucida, 459-460, 462-464
- Zona protein receptors
alteration of, 488-491
identification of, 487-488
- ZP3. *See* Glycoprotein ZP3

